These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 30281999)

  • 1. Optimization of maintenance therapy of Risperidone with CYP2D6 genetic polymorphisms through an extended translational framework-based prediction of target occupancies/clinical outcomes.
    Li HQ; Xu JY; Gao YY; Jin L
    Pharmacol Res; 2018 Nov; 137():135-147. PubMed ID: 30281999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simultaneous in-vivo receptor occupancy assays for serotonin 1A, 2A, and dopamine 2 receptors with the use of non-radiolabelled tracers: Proposed method in screening antipsychotics.
    Thentu JB; Nirogi R; Bhyrapuneni G; Ajjala DR; Aleti RR; Palacharla RC
    J Pharmacol Toxicol Methods; 2017; 85():22-28. PubMed ID: 28063918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia.
    Kapur S; Zipursky RB; Remington G
    Am J Psychiatry; 1999 Feb; 156(2):286-93. PubMed ID: 9989565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of genetic correlates of response to Risperidone: Findings of a multicentric schizophrenia study from India.
    Kaur G; Gupta D; Chavan BS; Sinhmar V; Prasad R; Tripathi A; Garg PD; Gupta R; Khurana H; Gautam S; Margoob MA; Aneja J
    Asian J Psychiatr; 2017 Oct; 29():174-182. PubMed ID: 28692863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of Antipsychotic Dose Reduction in Late-Life Schizophrenia: A Prospective Dopamine D2/3 Receptor Occupancy Study.
    Graff-Guerrero A; Rajji TK; Mulsant BH; Nakajima S; Caravaggio F; Suzuki T; Uchida H; Gerretsen P; Mar W; Pollock BG; Mamo DC
    JAMA Psychiatry; 2015 Sep; 72(9):927-34. PubMed ID: 26131622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risperidone-related weight gain: genetic and nongenetic predictors.
    Lane HY; Liu YC; Huang CL; Chang YC; Wu PL; Lu CT; Chang WH
    J Clin Psychopharmacol; 2006 Apr; 26(2):128-34. PubMed ID: 16633140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients.
    Nyberg S; Eriksson B; Oxenstierna G; Halldin C; Farde L
    Am J Psychiatry; 1999 Jun; 156(6):869-75. PubMed ID: 10360125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physiologically Based Modeling Approach to Predict Dopamine D2 Receptor Occupancy of Antipsychotics in Brain: Translation From Rat to Human.
    Wong YC; Centanni M; de Lange ECM
    J Clin Pharmacol; 2019 May; 59(5):731-747. PubMed ID: 30676661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using pharmacokinetic-pharmacodynamic modelling as a tool for prediction of therapeutic effective plasma levels of antipsychotics.
    Olsen CK; Brennum LT; Kreilgaard M
    Eur J Pharmacol; 2008 Apr; 584(2-3):318-27. PubMed ID: 18325493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risperidone plasma levels, clinical response and side-effects.
    Riedel M; Schwarz MJ; Strassnig M; Spellmann I; Müller-Arends A; Weber K; Zach J; Müller N; Möller HJ
    Eur Arch Psychiatry Clin Neurosci; 2005 Aug; 255(4):261-8. PubMed ID: 15565299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic-pharmacodynamic modelling of antipsychotic drugs in patients with schizophrenia: part II: the use of subscales of the PANSS score.
    Pilla Reddy V; Kozielska M; Suleiman AA; Johnson M; Vermeulen A; Liu J; de Greef R; Groothuis GM; Danhof M; Proost JH
    Schizophr Res; 2013 May; 146(1-3):153-61. PubMed ID: 23473811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic-pharmacodynamic analysis of antipsychotics-induced extrapyramidal symptoms based on receptor occupancy theory incorporating endogenous dopamine release.
    Matsui-Sakata A; Ohtani H; Sawada Y
    Drug Metab Pharmacokinet; 2005 Jun; 20(3):187-99. PubMed ID: 15988121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atypical antipsychotics: mechanism of action.
    Seeman P
    Can J Psychiatry; 2002 Feb; 47(1):27-38. PubMed ID: 11873706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.
    Swainston Harrison T; Perry CM
    Drugs; 2004; 64(15):1715-36. PubMed ID: 15257633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment.
    Plesnicar BK; Zalar B; Breskvar K; Dolzan V
    J Psychopharmacol; 2006 Nov; 20(6):829-33. PubMed ID: 16478753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic-pharmacodynamic modeling of the D₂ and 5-HT (2A) receptor occupancy of risperidone and paliperidone in rats.
    Kozielska M; Johnson M; Pilla Reddy V; Vermeulen A; Li C; Grimwood S; de Greef R; Groothuis GM; Danhof M; Proost JH
    Pharm Res; 2012 Jul; 29(7):1932-48. PubMed ID: 22437487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of two semi-mechanistic models for prolactin release and prediction of receptor occupancy following administration of dopamine D2 receptor antagonists in rats.
    Taneja A; Vermeulen A; Huntjens DRH; Danhof M; De Lange ECM; Proost JH
    Eur J Pharmacol; 2016 Oct; 789():202-214. PubMed ID: 27395799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone.
    Scordo MG; Spina E; Facciolà G; Avenoso A; Johansson I; Dahl ML
    Psychopharmacology (Berl); 1999 Dec; 147(3):300-5. PubMed ID: 10639689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modelling Age-Related Changes in the Pharmacokinetics of Risperidone and 9-Hydroxyrisperidone in Different CYP2D6 Phenotypes Using a Physiologically Based Pharmacokinetic Approach.
    Kneller LA; Hempel G
    Pharm Res; 2020 May; 37(6):110. PubMed ID: 32476097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical significance of a CYP2D6 poor metabolizer--a patient with schizophrenia on risperidone treatment.
    Bozina N; Jovanović N; Lovrić M; Medved V
    Ther Drug Monit; 2008 Dec; 30(6):748-51. PubMed ID: 18806696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.